Aethlon Medical (AEMD) Advances Cancer Trials and Operational Efficiency Improvements

Aethlon Medical Advances Cancer Treatment Trials Amid Operational Efficiency Improvements

Aethlon Medical, Inc. (Nasdaq: AEMD) makes notable strides in its clinical trials for the Hemopurifier® device, designed to treat cancer and severe infectious diseases. The company successfully concludes the first treatment cohort of its Australian trial, focusing on solid tumor patients who have not responded to anti-PD-1 immunotherapy. All participants in this cohort tolerate the four-hour treatment without experiencing serious adverse events or dose-limiting toxicities. This positive outcome is critical as it demonstrates the device's safety profile, which is essential for advancing to subsequent phases of clinical testing.

In a significant development, Aethlon amends its trial protocol to broaden eligibility for participation. Previously restricted to patients on specific anti-PD-1 treatments, the new guidelines allow individuals on any treatment regimen, including widely used agents like pembrolizumab (Keytruda®) and nivolumab (Opdivo®), to enter the trial. This change is expected to enhance patient recruitment, aligning the study more closely with the current standards of care and expanding the potential impact of the Hemopurifier. Preclinical data further supports Aethlon's innovative approach, showing a remarkable 98.5% efficacy in removing platelet-derived extracellular vesicles during simulated treatments.

From an operational standpoint, Aethlon Medical shows significant improvements, reporting a 31.6% reduction in operating expenses. This reduction enhances the company's financial health and operational efficiency, allowing it to invest further in critical research and development activities. The independent Data Safety Monitoring Board (DSMB) has reviewed the safety data and recommended the transition to a second cohort, where participants will receive two Hemopurifier treatments within a week. As all three clinical sites in Australia prepare to screen for this next group, Aethlon underscores its commitment to tackling pressing challenges in oncology and infectious diseases.

In parallel with its cancer research, Aethlon is progressing in its collaboration with UCSF on Long COVID investigations, with recent findings presented at the Keystone Symposium. This ongoing research highlights the company's dedication to addressing significant medical challenges beyond oncology. Aethlon Medical's upcoming conference call at 4:30 p.m. ET will provide further insights into these developments, reinforcing its position as a key player in innovative therapeutic solutions.